Works matching IS 17562856 AND DT 2015 AND VI 8 AND IP 6

Results: 8

Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome.

Published in:

Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 6, p. 328, doi. 10.1177/1756285615607726

By:

Schoonjans, An-Sofie;
Lagae, Lieven;
Ceulemans, Berten

Publication type:

Article

Future perspectives in target-specific immunotherapies of myasthenia gravis.

Published in:

Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 6, p. 316, doi. 10.1177/1756285615605700

By:

Dalakas, Marinos C.

Publication type:

Article

An update on the management of post-traumatic headache.

Published in:

Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 6, p. 311, doi. 10.1177/1756285615605699

By:

Obermann, Mark;
Naegel, Steffen;
Bosche, Bert;
Holle, Dagny

Publication type:

Article

A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis.

Published in:

Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 6, p. 294, doi. 10.1177/1756285615605698

By:

Braley, Tiffany J.;
Chervin, Ronald D.

Publication type:

Article

Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes.

Published in:

Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 6, p. 274, doi. 10.1177/1756285615605429

By:

Lycke, Jan

Publication type:

Article

Corrigendum.

Published in:: Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 6, p. 339, doi. 10.1177/1756285615605214
Publication type:: Article

Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Published in:

Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 6, p. 255, doi. 10.1177/1756285615602832

By:

Pavlovic, Dejan;
Patera, Andriani C.;
Nyberg, Fredrik;
Gerber, Marianne;
Liu, Maggie

Publication type:

Article

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit–risk ratio.

Published in:

Therapeutic Advances in Neurological Disorders, 2015, v. 8, n. 6, p. 245, doi. 10.1177/1756285615601360

By:

Safouris, Apostolos;
Triantafyllou, Nikos;
Parissis, John;
Tsivgoulis, Georgios

Publication type:

Article